Dr. Garrett Harvey

Dr. Garrett Harvey holds the position of VMD - Head of Medical Affairs at FidoCure®, a company recognized for being the first to introduce targeted medicine, traditionally used in human oncology, to canine cancer treatment. At FidoCure®, Dr. Harvey works with a team that has successfully treated thousands of dogs with cancer. The company’s approach involves DNA testing to detect genetic markers in dogs, which then guides the creation of personalized reports recommending targeted therapies. These therapies are made accessible through a network of partner compounding pharmacies. Dr. Harvey’s role enables veterinarians to apply these targeted treatments to each dog, considering their unique genetic profile. His work has contributed to the treatment of various cancers in dogs, including hemangiosarcoma and bladder cancer, and even some rare types. FidoCure® has also made strides in research and development, amassing 1.7 billion data points on canine cancer and publishing three peer-reviewed papers that demonstrate the positive impact of their work on patient outcomes. Additionally, the team has developed an innovative bioinformatics pipeline that helps reduce sequencing costs, thereby expanding access to precision therapeutics in canine oncology. All targeted therapies at FidoCure® are sourced from facilities that are licensed and inspected by the Board of Pharmacy, ensuring that they are compounded from human-grade active pharmaceutical ingredients.